|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.22 USD | +0.88% |
|
+2.85% | -1.79% |
| Capitalization | 2.17B 1.85B 1.71B 1.6B 2.99B 200B 3.16B 19.59B 7.78B 94.32B 8.15B 7.99B 343B | P/E ratio 2025 * |
38.3x | P/E ratio 2026 * | 26.9x |
|---|---|---|---|---|---|
| Enterprise value | 2.04B 1.74B 1.61B 1.5B 2.8B 187B 2.97B 18.39B 7.3B 88.53B 7.65B 7.5B 322B | EV / Sales 2025 * |
1.6x | EV / Sales 2026 * | 1.34x |
| Free-Float |
76.13% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Progyny, Inc.
| 1 day | +0.88% | ||
| 1 week | +2.85% | ||
| Current month | -1.79% | ||
| 1 month | -1.37% | ||
| 3 months | +29.33% | ||
| 6 months | +7.50% | ||
| Current year | -1.79% |
| 1 week | 24.62 |  | 25.78 |
| 1 month | 24.1 | | 28.75 |
| Current year | 24.1 | | 28.75 |
| 1 year | 17.98 | | 28.75 |
| 3 years | 13.39 | | 44.95 |
| 5 years | 13.39 | | 68.32 |
| 10 years | 13.29 | | 68.32 |
| Manager | Title | Age | Since |
|---|---|---|---|
Peter Anevski
CEO | Chief Executive Officer | 59 | 01/01/2022 |
Mark Livingston
DFI | Director of Finance/CFO | 60 | 15/09/2020 |
Steven Leist
CTO | Chief Tech/Sci/R&D Officer | - | 11/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
David Schlanger
CHM | Chairman | 66 | 01/01/2022 |
Norman Payson
BRD | Director/Board Member | 51 | 16/12/2016 |
Peter Anevski
BRD | Director/Board Member | 59 | 01/01/2022 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.88% | +2.85% | +14.53% | -24.78% | 2.17B | |
| +0.50% | +7.62% | -32.75% | -26.67% | 323B | |
| -0.32% | -1.02% | -7.55% | -22.36% | 82.46B | |
| -0.42% | +2.57% | -5.35% | -9.40% | 74.58B | |
| +0.08% | -2.48% | -9.29% | -46.11% | 32.05B | |
| +1.48% | +0.74% | -29.22% | -39.19% | 22.65B | |
| +1.58% | +5.48% | -34.10% | -32.09% | 10.38B | |
| +0.85% | +5.82% | +63.42% | +94.05% | 4.76B | |
| Average | +0.44% | +1.25% | -5.04% | -13.32% | 68.97B | |
| Weighted average by Cap. | -0.36% | +3.84% | -22.78% | -24.39% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.28B 1.09B 1.01B 941M 1.75B 117B 1.86B 11.51B 4.57B 55.43B 4.79B 4.69B 202B | 1.4B 1.19B 1.1B 1.03B 1.92B 128B 2.04B 12.6B 5B 60.67B 5.24B 5.14B 221B |
| Net income | 59.37M 50.49M 46.8M 43.74M 81.53M 5.45B 86.42M 535M 212M 2.58B 223M 218M 9.37B | 85.14M 72.41M 67.12M 62.72M 117M 7.82B 124M 767M 305M 3.69B 319M 313M 13.43B |
| Net Debt | -134M -114M -105M -98.37M -183M -12.27B -194M -1.2B -478M -5.79B -501M -490M -21.07B | -304M -258M -239M -224M -417M -27.9B -442M -2.74B -1.09B -13.17B -1.14B -1.12B -47.92B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/01/26 | 25.22 $ | +0.88% | 1,953,683 |
| 22/01/26 | 25.00 $ | -1.77% | 1,430,142 |
| 21/01/26 | 25.45 $ | +0.28% | 1,182,153 |
| 20/01/26 | 25.38 $ | +3.51% | 1,675,422 |
| 16/01/26 | 24.52 $ | +0.86% | 1,348,594 |
Delayed Quote Nasdaq, 24 January 2026 at 08:00 am AEDT
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PGNY Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition